BPC-157

BPC-157 (Body Protective Compound 157) emerged from Croatian gastroenterology research in the 1990s, when Dr. Predrag Sikiric and colleagues at the University of Zagreb isolated a 15-amino-acid sequence from a protective protein found in human gastric juice — originally studied for its role in shielding the stomach lining, a line of inquiry that expanded into broader tissue-repair research. What it is: BPC-157 is a synthetic pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), stable in both acidic and basic environments. This stability has made it a subject of interest for both oral and injectable delivery. Proposed Mechanisms & Research Findings: Preclinical studies — conducted exclusively in cell cultures and rodent models — suggest BPC-157 may promote tissue repair via upregulation of VEGFR2 (angiogenesis), increased growth hormone receptor expression in tendon fibroblasts, and modulation of nitric oxide signaling. Animal studies report accelerated healing of tendons, muscles, ligaments, and gastric mucosa. None of these findings have been confirmed in controlled human clinical trials. Regulatory & Safety Status: BPC-157 is not approved for human use by the FDA, Health Canada, or any major regulatory authority. The FDA has listed it on the Category 2 Bulk Drug Substances list due to safety concerns and insufficient evidence for compounded use. No Phase II or III human trials have been completed, leaving dosage ranges, side effect profiles, and pharmacokinetics entirely unestablished. Sourcing from gray-market vendors carries serious risks: unverified purity, heavy metal contamination, and non-sterile injectables. Athletic & Anti-Doping Status: WADA classifies BPC-157 under Section S0 — Non-Approved Substances — prohibited both in- and out-of-competition. USADA has issued explicit warnings that its use constitutes a doping violation with career-ending consequences.